THE ANTI-TUBERCULOSIS ANTIBIOTIC OF RIFAPENTINE: PERSPECTIVES OF CLINICAL USE
https://doi.org/10.21292/2075-1230-2018-96-12-55-61
Abstract
Anti-tuberculosis chemotherapy makes a main component of therapy and involves the long-term treatment with the optimal combination of drugs. Tuberculosis incidence has been noted to be high in the risk groups (those receiving immunosuppressive therapy, people living with HIV, etc.); such patients are treated for their main disease in addition to anti-tuberculosis chemotherapy. A large number of drugs used simultaneously in treatment regimens can reduce patient's adherence to treatment, deteriorate drug tolerance and increase the frequency of adverse reactions. Using slow-release drugs within treatment regimens is one of the ways to reduce polypragmasy. One of them is rifapentine, recommended in the Russian Federation for the treatment of latent tuberculosis infection in patients with HIV infection.
The review presents information about the efficacy, tolerability and safety of rifapentine within treatment regimens for active and latent tuberculosis infection.
About the Authors
A. G. Samoylova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Doctor of Medical Sciences, Deputy Director for Research
4, Dostoevsky St., Moscow, 127473
E. I. Veselova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Junior Researcher
4, Dostoevsky St., Moscow, 127473
O. V. Lovacheva
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor, Chief Researcher
4, Dostoevsky St., Moscow, 127473
G. D. Kaminsky
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Doctor of Medical Sciences, Head of Department
4, Dostoevsky St., Moscow, 127473
References
1. Federalnye klinicheskie rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya. [Federal clinical recommendations for diagnostics and treatment of respiratory tuberculosis]. (written by Vasilyeva I.А., Аksenova V.А., Ergeshov А.E., Maryandyshev А.O., Samoylova А.G., Bagdasaryan T.R., Komissarova O.G., Lovacheva O.V., Perfiliev А.V., Karpina N.L., Kayukova S.I., Stakhanov V.А, Skornyakov S.N., Balasanyants G.S., Morozova T.I., Valiev R.Sh., Kazimirova N.E., Kazenny B.Ya., Klevno N.I., Baryshnikova L.А., Puzanov V.А., Popov S.А.). Moscow, Triada Publ., 2014, pp. 55.
2. Federalnye klinicheskie rekomendatsii po profilaktike, diagnostike i lecheniyu tuberkuleza u bolnykh VICH-infektsiey. [Federal clinical recommendations on prevention, diagnostics and treatment of tuberculous in HIV patients]. (written by Vasilyeva I.А., Voronin E.E., Pokrovskiy V.V., Аksenova V.А., Bagdasaryan T.R., Baryshnikova L.А., Valiev R.Sh., Viktorova I.B., Zagdyn Z.M., Zimina V.N., Kazimirova N.E., Karpina N.L., Kayukova S.I., Klevno N.I., Kononchuk O.N., Kravchenko А.V., Larionova E.E., Maryandyshev А.O., Mikhaylovskiy А.M., Morozova T.I., Okhtyarkina V.V., Panteleev А.M., Samoylova А.G., Sevastyanova E.V., Sinitsyn M.V., Skornyakov S.N., Stakhanov V.А., Chernousova L.N., Ergeshov А.E., Yurin O.G.). Moscow, 2016.
3. Alfarisi O., Alghamdi W.A., Al-Shaer M.H., Dooley K.E., Peloquin C.A. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? Expert. Rev. Clin. Pharmacol., 2017, no. 10, pp. 1027-1036. doi: 10.1080/17512433.2017.1366311.Epub 2017 Aug 18.
4. Benator D., Bhattacharya M., Bozeman L., Burman W., Cantazaro A., Chaisson R., Gordin F., Horsburgh C.R., Horton J., Khan A., Lahart C., Metchock B., Pachucki C., Stanton L., Vernon A., Villarino M.E., Wang Y.C., Weiner M., Weis S. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet, 2002, vol. 360 (9332), pp. 528-534.
5. Bock N.N., Sterling T.R., Hamilton C.D., Pachucki C., Wang Y.C., Conwell D.S., Mosher A., Samuels M., Vernon A. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am. J. Respir. Crit. Care Med., 2002, vol. 165, no. 11, pp. 1526-1530.
6. Brooks K.M., George J.M., Pau A.K., Rupert A., Mehaffy C., De P., Dobos K.M., Kellogg A., McLaughlin M., McManus M., Alfaro R.M., Hadigan C., Kovacs J.A., Kumar P. Cytokine-mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine. Clin. Infect. Dis., 2018, Feb. 3. doi: 10.1093/cid/ciy082. [Epub ahead of print].
7. Cruz A.T., Starke J.R. Completion rate and safety of tuberculosis infection treatment with shorter regimens. Pediatrics, 2018, vol. 141, no. 2. pii: e20172838. doi: 10.1542/peds.2017-2838.
8. Dooley K., Flexner C., Hackman J., Peloquin C.A., Nuermberger E., Chaisson R.E., Dorman S.E. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob. Agents Chemother., 2008, vol. 52, no. 11, pp. 4037-4042. doi: 10.1128/AAC.00554-08. Epub 2008 Sep 2.
9. Dorman S.E., Savic R.M., Goldberg S., Stout J.E., Schluger N., Muzanyi G., Johnson J.L., Nahid P., Hecker E.J., Heilig C.M., Bozeman L., Feng P.J., Moro R.N., MacKenzie W., Dooley K.E., Nuermberger E.L., Vernon A., Weiner M. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am. J. Respir. Crit. Care Med., 2015, vol. 191, no. 3, pp. 333-343. doi: 10.1164/rccm.201410-1843OC.
10. Dorman S.E., Goldberg S., Stout J.E., Muzanyi G., Johnson J.L., Weiner M., Bozeman L., Heilig C.M., Feng P.J., Moro R., Narita M., Nahid P., Ray S., Bates E., Haile B., Nuermberger E.L., Vernon A., Schluger N.W. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J. Infect. Dis., 2012, vol. 206, no. 7, pp. 1030-1040. Epub 2012 Jul 30.
11. Getahun H., Matteelli A., Abubakar I., Aziz M.A., Baddeley A., Barreira D., Den Boon S., Borroto Gutierrez S.M., Bruchfeld J. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur. Respir. J., 2015, vol. 46, no. 6, pp. 1563-1576. doi: 10.1183/13993003.01245-2015. Epub 2015 Sep 24.
12. Jindani A., Harrison T.S., Nunn A.J., Phillips P.P., Churchyard G.J., Charalambous S., Hatherill M., Geldenhuys H., McIlleron H.M. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N. Engl. J. Med., 2014, vol. 371, no. 17, pp. 1599-1608. doi: 10.1056/NEJMoa1314210.
13. Marcus Conde B., Mello F.C., Duarte R.S., Cavalcante S.C., Rolla V., Dalcolmo M., Loredo C., Durovni B., Armstrong D.T., Efron A., Barnes G.L., Marzinke M.A., Savic R.M., Dooley K.E., Cohn S., Moulton L.H., Chaisson R.E., Dorman S.E. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. Cond. PLoS One, 2016, vol. 11, no. 5, pp. e0154778. Published online 2016 May 9. doi: 10.1371/journal.pone.0154778.
14. Martinson N.A., Barnes G.L., Moulton L.H., Msandiwa R., Hausler H., Ram M., McIntyre J.A., Gray G.E., Chaisson R.E. New regimens to prevent tuberculosis in adults with HIV infection. N. Engl. J. Med., 2011, vol. 365, no. 1, pp. 11-20. doi: 10.1056/NEJMoa1005136.
15. Michelle K. Haas, Robert W. Belknap A review of rifapentine for treating active and latent tuberculosis. Clin. Invest. (Lond)., 2015, vol. 5, no. 11.
16. Pease С., Hutton B., Yazdi F., Wolfe D., Hamel C., Quach P., Skidmore B., Moher D., Alvarez G.G. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis., 2017, vol. 17, pp. 265. Published online 2017 Apr 11. doi: 10.1186/s12879-017-2377-x.
17. Podany A.T., Bao Y., Swindells S., Fletcher C.V. Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving Rifapentine and Isoniazid for tuberculosis prevention. Clin. Infect. Dis., 2015, vol. 61, no. 8, pp. 1322-1327.
18. Sterling T.R., Villarino M.E., Borisov A.S., Shang N., Gordin F., Bliven-Sizemore E., Hackman J., Hamilton C.D., Menzies D., Kerrigan A., Weis S.E., Weiner M., Wing D., Conde M.B., Bozeman L., Horsburgh C.R.Jr., Chaisson R.E. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med., 2011, vol. 365, no. 23, pp. 2155-2166. doi:10.1056/NEJMoa1104875.
19. Villarino M.E., Scott N.A., Weis S.E., Weiner M., Conde M.B., Jones B., Nachman S., Oliveira R., Moro R.N., Shang N., Goldberg S.V., Sterling T.R. Treatment for Preventing Tuberculosis in Children and Adolescents. A Randomized Clinical Trial of a 3-Month, 12-Dose Regimen of a Combination of Rifapentine and Izoniazid. 2015, vol. 169, no. 3, pp. 247-255.
20. Weiner M., Egelund E.F., Engle M., Kiser M., Prihoda T.J., Gelfond J.A., Mac Kenzie W., Peloquin C.A. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J. Antimicrob. Chemother., 2014, vol. 69, no. 4, pp. 1079-1085. doi: 10.1093/jac/dkt483. Epub 2013 Dec 15.
21. Weiner M., Savic R.M., Kenzie W.R., Wing D., Peloquin C.A., Engle M., Bliven E., Prihoda T.J., Gelfond J.A., Scott N.A., Abdel-Rahman S.M., Kearns G.L., Burman W.J., Sterling T.R., Villarino M.E. Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with Rifapentine and Isoniazid for latent tuberculosis infection. J. Pediatrics Infect. Dis. Soc., 2014, vol. 3, no. 2, pp. 132-145. doi: 10.1093/jpids/pit077.Epub 2014 Jan 16.
22. Winter H., Egizi E., Murray S., Erondu N., Ginsberg A., Rouse D.J., Severynse-Stevens D., Pauli E. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects. Antimicrob. Agents Chemother., 2015, vol. 59, no. 2, pp. 1219-1224. doi: 10.1128/AAC.04171-14. Epub 2014 Dec 15.
Review
For citations:
Samoylova A.G., Veselova E.I., Lovacheva O.V., Kaminsky G.D. THE ANTI-TUBERCULOSIS ANTIBIOTIC OF RIFAPENTINE: PERSPECTIVES OF CLINICAL USE. Tuberculosis and Lung Diseases. 2018;96(12):55-61. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-12-55-61
Views:
2909
Email this article 